Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.

Is (S)-norketamine an alternative antidepressant for esketamine?

Open access
Hashimoto, Kenji, Yang, Chun · 2019 · European Archives of Psychiatry and Clinical Neuroscience

Abstract

The N-methyl-d-aspartate receptor (NMDAR) antagonist (R,S)ketamine has been hailed as the most important advance in the treatment of depression for the past 50 years. The rapid and sustained antidepressant effects of (R,S)-ketamine have spurred a great deal of research interest, with growing off-label use for the treatment of depression, although the concerns about the safety of repeated (R,S)-ketamine infusions persist [1]. (R,S)-ketamine (Ki = 0.53 μM for NMDAR) is a racemic mixture containing equal parts of (R)-ketamine (or arketamine) (Ki = 1.4 μM for NMDAR) and (S)-ketamine (or esketamine) (Ki = 0.30 μM for NMDAR) (Fig. 1). Previously, we reported that (R)-ketamine showed greater potency and longer lasting antidepressant effects than esketamine in animal models of depression [2]. Unlike esketamine, (R)-ketamine does not induce psychotomimetic side effects or exhibit abuse potential in rodents [3]. A positron emission tomography study using conscious monkeys demonstrated a marked reduction in dopamine D2/3 receptor binding in the monkey striatum after a single infusion of esketamine (0.5 mg/kg for 40 min), suggesting a marked release of dopamine from presynaptic terminal [4]. Interestingly, it is reported that a single infusion of esketamine (0.5 mg/kg for 40 min) caused psychotomimetic and dissociative symptoms (e.g., strange experiences like a feeling of floating in outer space or depersonalization/derealization) in patients with treatment-resistant depression [5]. Therefore, it is suggested that esketamine-induced dopamine release might be associated with the acute psychotomimetic and dissociative side effects in humans. Collectively, (R)-ketamine could be a safer antidepressant in humans than esketamine [2–4] . The Janssen Pharmaceutical Companies of Johnson & Johnson has been developing esketamine nasal spray as the novel antidepressant. Two phase 2 randomized clinical trials of intranasal esketamine have been reported. Daly et al. [6] reported the efficacy of intranasal esketamine (28, 56, or 84 mg twice weekly) for the rapid reduction of symptoms of depression and suicidality in treatment-resistant patients. Change in Montgomery–Åsberg Depression Rating Scale (MADRS) total score in all three esketamine groups was superior to placebo, with a significant dose–response relationship [6]. Furthermore, Canuso et al. [7] reported the efficacy and safety of intranasal esketamine for the rapid reduction of symptoms of depression and suicidality in patients at imminent risk for suicide. Esketamine (84 mg twice weekly for 4 weeks) along with antidepressant treatment significantly decreased suicidal symptoms and depression at both 4 and 24 h; however, these effects did not differ from those of placebo after 4 weeks of treatment. In contrast, differences in suicide risk scores, as determined by clinical global judgment, were not statistically significant between the groups at any time point [7]. Dissociative symptoms began shortly after each infusion and attenuated after repeated doses. The abuse potential of intranasal esketamine was not specifically examined within this short trial [6, 7]. It seems that the effects of intranasal esketamine may be less potent than intravenous (R,S)-ketamine. At the American Psychiatric Association annual meeting in May 2018, the company presented mixed findings of two phase 3 trials for intranasal esketamine [8]. Adult treatment-resistant patients who received esketamine had a significantly greater drop in MADRS score from baseline at day 28 compared with placebo group. In contrast, 65 and older patients with treatment-resistant depression who received esketamine plus a newly initiated oral antidepressant had no statistical difference in change in the MADRS score from baseline to day 28 compared with placebo group [8]. The potential for ketamine abuse is one of the most important drawbacks of repeated ketamine infusions for treating mood disorders [9]. Ketamine-induced rewarding effects are associated with the potent inhibition of the NMDAR in the brain. Esketamine is metabolized into (S)-norketamine (Ki = 1.70 μM for NMDAR) by the microsomal cytochrome P450 system (Fig. 1). Preclinical studies have revealed the * Kenji Hashimoto hashimoto@faculty.chiba-u.jp

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1007/s00406-018-0922-2

Cites

9 of 9 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 Chemical structure of (R,S)-ketamine, (S)-ketamine (or esketamine) and its metabolite (S)-norketamine. (S)-ketamine is metabolized into (S)-norketamine by the microsomal cytochrome P450 system. The values in parentheses are the inhibitor constant values for NMDAR (10)
Fig. 1 Chemical structure of (R,S)-ketamine, (S)-ketamine (or esketamine) and its metabolite (S)-norketamine. (S)-ketamine is metabolized into (S)-norketamine by the microsomal cytochrome P450 system. The values in parentheses are the inhibitor constant values for NMDAR (10)CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 9 references

Research works printed but not linked: 1

  1. Psychiatric News (2018) J&J presents mixed findings for esketamine nasal spray at APA Annual Meeting. https://psychnews.psychiatryonline.org/doi/full/10.1176/appi.pn.2018.pp5a2 · doi:10.1176/appi.pn.2018.pp5a2

Cited by

See all 38

Metadata

Authors
Hashimoto, K., & Yang, C.
Affiliations
  • Chiba University (JP)
  • Tongji Hospital (CN)
Corresponding author
Hashimoto, Kenji
Venue
European Archives of Psychiatry and Clinical Neuroscience
Published
2018-07-14
Volume
269
Issue
7
Pages
867-868
ISSN
  • 0003-9373 (ISSN-L)
  • 0940-1334
  • 1433-8491
OpenAlex
W2884332078
Cited by
37
References
9
Citations by year
2026: 2 · 2025: 2 · 2024: 3 · 2023: 3 · 2022: 6 · 2021: 4 · 2020: 10 · 2019: 6 · 2018: 1
FWCI
3.39
Type
journal article
Language
en
Open access
Licence
Locations
  • European Archives of Psychiatry and Clinical Neuroscience (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
Funders
  • Japan Agency for Medical Research and Development (JP18dm0107119)
  • National Natural Science Foundation of China (81703482)
Topics
  • Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
  • Health Sciences › Medicine › Psychiatry and Mental health › Electroconvulsive Therapy Studies
  • Life Sciences › Neuroscience › Biological Psychiatry › Tryptophan and brain disorders
Keywords
esketamine, antidepressants, ketamine analogues, treatment-resistant depression
MeSH terms
Animals, Antidepressive Agents, Depression, Humans, Ketamine

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Is (S)-norketamine an alternative antidepressant for esketamine? https://app.cochat.ai/papers/10.1007/s00406-018-0922-2
The paper
Hashimoto, K., & Yang, C. (2019). Is (S)-norketamine an alternative antidepressant for esketamine? European Archives of Psychiatry and Clinical Neuroscience. https://doi.org/10.1007/s00406-018-0922-2

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.